We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+44.97%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$3.38B
AUM Growth
+$1.14B
Cap. Flow
+$493M
Cap. Flow %
14.6%
Top 10 Hldgs %
62.24%
Holding
58
New
13
Increased
11
Reduced
2
Closed
6

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$180M
2
NVTA
Invitae Corporation
NVTA
+$156M
3
BLFS icon
BioLife Solutions
BLFS
+$54.6M
4
FDMT icon
4D Molecular Therapeutics
FDMT
+$32.2M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$24.7M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$119M
2
AMRS
Amyris Inc.
AMRS
+$23.6M
3
ILMN icon
Illumina
ILMN
+$9.27M
4
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$7.69M
5
LEGN icon
Legend Biotech
LEGN
+$4.31M

Sector Composition

Rank Sector Weight
1 Healthcare 84.21%
2 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVTA
1
DELISTED
Invitae Corporation
NVTA
$514M 15.23%
12,298,038
+3,264,095
+36% +$156M
BLFS icon
2
BioLife Solutions
BLFS
$1.56B
$297M 8.79%
7,440,107
+1,600,000
+27% +$54.6M
FATE icon
3
Fate Therapeutics
FATE
$294M
$277M 8.22%
3,050,000
– –
EXAS
4
DELISTED
Exact Sciences
EXAS
$197M 5.83%
+1,485,149
New +$180M
BPMC
5
DELISTED
Blueprint Medicines
BPMC
$174M 5.15%
1,550,000
– –
RLAY icon
6
Relay Therapeutics
RLAY
$4.04B
$158M 4.69%
3,808,894
– –
TWST icon
7
Twist Bioscience
TWST
$5.97B
$141M 4.19%
1,000,000
– –
PACB icon
8
Pacific Biosciences
PACB
$444M
$130M 3.84%
5,000,000
+500,000
+11% +$8.5M
DNLI icon
9
Denali Therapeutics
DNLI
$3.67B
$110M 3.25%
1,310,000
– –
AGIO icon
10
Agios Pharmaceuticals
AGIO
$1.84B
$103M 3.05%
2,375,000
+625,000
+36% +$24.7M
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$29.1B
$101M 3%
780,000
+160,000
+26% +$21.4M
CDXS icon
12
Codexis
CDXS
$157M
$94.5M 2.8%
4,330,000
+345,000
+9% +$5.68M
SRPT icon
13
Sarepta Therapeutics
SRPT
$1.63B
$90.4M 2.68%
530,000
– –
CDNA icon
14
CareDx
CDNA
$2.48B
$86.5M 2.56%
1,193,335
– –
RVMD icon
15
Revolution Medicines
RVMD
$38.8B
$64.7M 1.92%
1,634,535
– –
CNST
16
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$51.4M 1.52%
1,785,000
+805,000
+82% +$20.3M
GBIO
17
DELISTED
Generation Bio
GBIO
$45.7M 1.35%
161,121
– –
DMTK
18
DELISTED
DermTech, Inc. Common Stock
DMTK
$44.4M 1.32%
1,370,000
-58,572
-4% -$830K
BNR
19
Burning Rock Biotech
BNR
$95M
$44.4M 1.32%
192,215
– –
ADPT icon
20
Adaptive Biotechnologies
ADPT
$3.71B
$42.2M 1.25%
713,125
– –
CRSP icon
21
CRISPR Therapeutics
CRSP
$4.86B
$40.8M 1.21%
266,430
– –
BLUE
22
DELISTED
bluebird bio
BLUE
$39.6M 1.17%
70,638
– –
ADVM
23
DELISTED
Adverum Biotechnologies
ADVM
$39.6M 1.17%
365,000
+90,000
+33% +$11.1M
ONC
24
BeOne Medicines Ltd
ONC
$32.3B
$38.8M 1.15%
150,000
– –
BEAM icon
25
Beam Therapeutics
BEAM
$2.66B
$37.6M 1.11%
+460,000
New +$22.6M
1
2 3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Casdin Capital held 58 positions worth $3.38B, up 51% from $2.23B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Casdin Capital deployed $493M of net new capital in Q4 2020, opening 13 new positions and adding to 11 existing holdings. Its largest new stake was Exact Sciences: 1,485,149 shares worth $197M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 81% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $2.26M trimmed.

  • Casdin Capital's largest Q4 2020 buy was Exact Sciences: 1,485,149 shares worth $197M.
  • Casdin Capital added most to Invitae Corporation in Q4 2020, an estimated $156M increase.
  • Casdin Capital's biggest Q4 2020 reduction was Fulcrum Therapeutics, cutting an estimated $2.26M.
  • Casdin Capital fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $119M.
  • Casdin Capital's ten largest holdings make up 62% of its $3.38B portfolio in Q4 2020.
  • Casdin Capital opened 13 new positions and closed 6 in Q4 2020.
  • Casdin Capital's portfolio value rose 51% quarter-over-quarter to $3.38B.

Based on Casdin Capital's 13F filing for Q4 2020, filed 16 Feb 2021.